List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones
Featured News & Press Releases
Apr 06, 2022: Antengene's pivotal "MARCH" study to evaluate selinexor (ATG-010) in relapsed or refractory multiple myeloma published in BMC Medicine
Mar 29, 2022: Antengene announces IND approval in China for a phase II study of Eltanexor (ATG-016) in patients with High-Risk Myelodysplastic Syndrome
Mar 16, 2022: Karyopharm announces upcoming presentations of phase 3 SIENDO study of selinexor in patients with advanced or recurrent endometrial cancer
Mar 09, 2022: Antengene announces XPOVIO approved by the TGA in Australia for the treatment of relapsed and/or refractory multiple myeloma and triple class-refractory multiple myeloma
Mar 01, 2022: Antengene announces XPOVIO regulatory approval in Singapore for the treatment of relapsed and/or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma in three indications
Mar 01, 2022: Karyopharm provides U.S. regulatory update on Selinexor in advanced or recurrent Endometrial Cancer
Feb 08, 2022: Karyopharm announces Phase 3 SIENDO study meets primary endpoint with statistically significant increase in progression-free survival in patients with advanced or recurrent endometrial cancer
Jan 24, 2022: Karyopharm receives orphan drug designation from FDA for eltanexor for the treatment of myelodysplastic syndromes
Dec 29, 2021: Antengene announces first patient dosed in REACH study of ATG-016 for the treatment of advanced solid tumors
Dec 18, 2021: Antengene announces NDA approval by NMPA for XPOVIO, China's first XPO1 inhibitor, for the treatment of adults with relapsed or refractory multiple myeloma
Dec 14, 2021: Antengene presents results of phase 1b TOUCH trial of Selinexor for the treatment of T and NK-Cell lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
Dec 11, 2021: Karyopharm announces presentation of updated phase 2 selinexor data in patients with myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
Dec 06, 2021: Karyopharm announces dosing of first patient in a new phase 2 study evaluating single-agent selinexor versus physician's choice in previously treated myelofibrosis
Dec 02, 2021: Karyopharm completes patient recruitment in phase 3 SIENDO study of selinexor in patients with endometrial cancer
Nov 18, 2021: Antengene announces IND approval in China for a phase I/II Study of Selinexor (ATG-010) in patients with non-Hodgkin lymphoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Biogen Inc, 2022
Pipeline by CanBas Co Ltd, 2022
Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
Pipeline by Karyopharm Therapeutics Inc, 2022
Pipeline by Oita University Institute of Advanced Medicine Inc, 2022
Pipeline by Wigen Biomedicine Technology (Shanghai) Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

Companies Mentioned
• Biogen Inc
• CanBas Co Ltd
• Jiangsu Carephar Pharmaceutical Co Ltd
• Karyopharm Therapeutics Inc
• Oita University Institute of Advanced Medicine Inc
• Wigen Biomedicine Technology (Shanghai) Co Ltd